Sartorius | Setting the Standard
in AAV Gene Therapy,
Together.
Adeno-associated virus
(AAV) gene therapies have
potential to transform the
way we treat certain
diseases. But to deliver
them successfully, robust
and cost-effective
production is critical.
Bring your therapy to
market faster and affordably with
end-to-end solutions that deliver
reproducible performance and
scalability with a simplified path
to regulatory approvals.
Setting the
Standard in Reproducible
Performance
-
Boost your
gene therapy process
performance with transfection
reagents and media optimized
for specific viral vectors
-
Ensure a
high-performing process with
automated, high-throughput,
and innovative technologies
that speed up development
timelines
-
Enhance
process understanding and
speed up decision-making with
intuitive data analytics.
Setting the
Standard in Simplified Scale-Up
-
Simplify the
transition to clinical and
commercial production with
scalable bioreactors, media,
and growth factors available
in a variety of formats
-
Streamline
revalidation and optimization
with scalable purification
platform solutions that raise
yield and reduce costs
-
Protect your
gene therapy product’s
performance during shipping
and handling with
preassembled, scalable storage
solutions.
Setting the
Standard for a Simplified Path to
Regulatory Compliance
-
Meet
efficacy and safety standards
with solutions backed by
rigorous quality-assurance
processes
-
Navigate
regulatory requirements with
our robust analytical tools,
testing and validation
services, and expert support
-
Protect
against contamination with raw
materials, media and buffer
filters, and single-use
solutions suitable for GMP
processes.
Learn More
About Our AAV Solutions &
Expertise:
|
